Matches in SemOpenAlex for { <https://semopenalex.org/work/W1809380315> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W1809380315 startingPage "5020" @default.
- W1809380315 abstract "In recent trials in patients with severe eosinophilic asthma a clinical benefit of treatment with anti-IL-5 antibodies was only demonstrated in terms of exacerbations. Aim of the present analyses was to identify patient characteristics associated with a treatment response beyond exacerbations.45 patients (27 [female], mean±SEM: age 51.3±1.3 yrs., FEV1 1.7±0.1 L / 57.2±2.7 % pred., FeNO 54.9±7.8 ppb, blood eosinophils 440/µl (median, range 10-2100/µl) were treated with an anti-IL-5-antibody for up to 12 months as part of blinded, randomized clinical trials (36 mepolizumab or reslizumab, 9 placebo).There was no FEV1 benefit after 1, 4 or 12 months in patients treated with placebo (median change 1.2%, -5.5% and -2.9%). In patients treated with anti-IL-5 FEV1 increased significantly by 17.9% (265 ml) after 1 month (p<0.001), by 17.3% (240 ml) after 4 months (p=0.002) and by 21.1% (295 ml) after 12 months (p=0.003). FEV1 response to anti-IL-5 was fast with maximum effects already seen after the first month. In patients with ≥600 eosinophils/µl FEV1 increased by 30.1% after 1 month and by 27.8% after 12 months, compared with 15.6% and 10.7% in patients with ≤300 eosinophils/µl (p=0.065, 1 month; p=0.277, 12 months). In contrast, sputum eosinophilia (≥ 2%) or FeNO did not predict FEV1 response (change in FEV1 after 1 month: sputum eosinophils <2% vs. ≥2% 17.2 vs. 11.0%, FeNO <50 ppb vs. ≥50 ppb 17.4 vs. 19.6%).In conclusion, the clinical benefits of anti-IL-5 in patients with eosinophilic asthma may well reach beyond exacerbations. Anti-IL-5 treatment seems to be most effective in asthma patients characterized by blood eosinophilia." @default.
- W1809380315 created "2016-06-24" @default.
- W1809380315 creator A5017375974 @default.
- W1809380315 creator A5029503227 @default.
- W1809380315 creator A5056192386 @default.
- W1809380315 date "2013-09-01" @default.
- W1809380315 modified "2023-10-02" @default.
- W1809380315 title "Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement" @default.
- W1809380315 hasPublicationYear "2013" @default.
- W1809380315 type Work @default.
- W1809380315 sameAs 1809380315 @default.
- W1809380315 citedByCount "0" @default.
- W1809380315 crossrefType "journal-article" @default.
- W1809380315 hasAuthorship W1809380315A5017375974 @default.
- W1809380315 hasAuthorship W1809380315A5029503227 @default.
- W1809380315 hasAuthorship W1809380315A5056192386 @default.
- W1809380315 hasConcept C126322002 @default.
- W1809380315 hasConcept C142724271 @default.
- W1809380315 hasConcept C181901479 @default.
- W1809380315 hasConcept C204787440 @default.
- W1809380315 hasConcept C27081682 @default.
- W1809380315 hasConcept C2776042228 @default.
- W1809380315 hasConcept C2776301714 @default.
- W1809380315 hasConcept C2777037409 @default.
- W1809380315 hasConcept C2777129736 @default.
- W1809380315 hasConcept C2777714996 @default.
- W1809380315 hasConcept C2777832160 @default.
- W1809380315 hasConcept C2778690821 @default.
- W1809380315 hasConcept C2779185760 @default.
- W1809380315 hasConcept C2781069245 @default.
- W1809380315 hasConcept C3018587741 @default.
- W1809380315 hasConcept C71924100 @default.
- W1809380315 hasConcept C74172505 @default.
- W1809380315 hasConcept C90924648 @default.
- W1809380315 hasConceptScore W1809380315C126322002 @default.
- W1809380315 hasConceptScore W1809380315C142724271 @default.
- W1809380315 hasConceptScore W1809380315C181901479 @default.
- W1809380315 hasConceptScore W1809380315C204787440 @default.
- W1809380315 hasConceptScore W1809380315C27081682 @default.
- W1809380315 hasConceptScore W1809380315C2776042228 @default.
- W1809380315 hasConceptScore W1809380315C2776301714 @default.
- W1809380315 hasConceptScore W1809380315C2777037409 @default.
- W1809380315 hasConceptScore W1809380315C2777129736 @default.
- W1809380315 hasConceptScore W1809380315C2777714996 @default.
- W1809380315 hasConceptScore W1809380315C2777832160 @default.
- W1809380315 hasConceptScore W1809380315C2778690821 @default.
- W1809380315 hasConceptScore W1809380315C2779185760 @default.
- W1809380315 hasConceptScore W1809380315C2781069245 @default.
- W1809380315 hasConceptScore W1809380315C3018587741 @default.
- W1809380315 hasConceptScore W1809380315C71924100 @default.
- W1809380315 hasConceptScore W1809380315C74172505 @default.
- W1809380315 hasConceptScore W1809380315C90924648 @default.
- W1809380315 hasLocation W18093803151 @default.
- W1809380315 hasOpenAccess W1809380315 @default.
- W1809380315 hasPrimaryLocation W18093803151 @default.
- W1809380315 hasRelatedWork W1870198817 @default.
- W1809380315 hasRelatedWork W1992347215 @default.
- W1809380315 hasRelatedWork W2074674261 @default.
- W1809380315 hasRelatedWork W2140688081 @default.
- W1809380315 hasRelatedWork W2349528884 @default.
- W1809380315 hasRelatedWork W2353675402 @default.
- W1809380315 hasRelatedWork W2368844188 @default.
- W1809380315 hasRelatedWork W2375917062 @default.
- W1809380315 hasRelatedWork W2376079253 @default.
- W1809380315 hasRelatedWork W2411890917 @default.
- W1809380315 hasRelatedWork W2554219999 @default.
- W1809380315 hasRelatedWork W2558951375 @default.
- W1809380315 hasRelatedWork W2778196172 @default.
- W1809380315 hasRelatedWork W2990215157 @default.
- W1809380315 hasRelatedWork W2990393830 @default.
- W1809380315 hasRelatedWork W3004163127 @default.
- W1809380315 hasRelatedWork W3032451891 @default.
- W1809380315 hasRelatedWork W3199115350 @default.
- W1809380315 hasRelatedWork W1906897993 @default.
- W1809380315 hasRelatedWork W1954005706 @default.
- W1809380315 hasVolume "42" @default.
- W1809380315 isParatext "false" @default.
- W1809380315 isRetracted "false" @default.
- W1809380315 magId "1809380315" @default.
- W1809380315 workType "article" @default.